Related Experiment Video
Updated: Aug 6, 2026

Endovascular Perforation Model for Subarachnoid Hemorrhage Combined with Magnetic Resonance Imaging (MRI)
Published on: December 16, 2021
Hematoma Volume in Apixaban vs. Rivaroxaban-Related Intracerebral Hemorrhage
Mitch Wilson1, Stephanie Vu2, Elizabeth Heistand2
1Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215-5491, USA. mitch.wilson857@gmail.com.
Background/Objective:
Among patients with intracerebral hemorrhage (ICH) associated with direct oral anticoagulant (DOAC) use, it is unknown whether hematoma volume differs according to DOAC agent. The primary objective of our study was to compare baseline hematoma volume between apixaban and rivaroxaban-related ICH.
Methods:
We evaluated consecutive patients with apixaban- and rivaroxaban-related spontaneous ICH admitted to a tertiary hospital between 2013 and 2024. We recorded baseline hematoma volume, hematoma expansion (> 6 cc or > 33%), and hospital mortality.
Results:
The cohort comprised 136 patients (age, median [IQR] 81 [73-87] years, 68 female [50.0%]); of whom 91 (66.9%) were taking apixaban and 45 (33.1%) were taking rivaroxaban at the time of the index ICH. There were no differences in demographics, comorbidities, or antiplatelet pretreatment between apixaban and rivaroxaban. Lobar hemorrhage location was more frequent with rivaroxaban (46.7% vs. 28.6%, P = 0.037). Rivaroxaban-related ICH patients had larger median baseline hematoma volumes (22.8 [8.0-58.0] mL vs. 12.2 [2.5-31.2] mL; P = 0.003) compared with apixaban. In multivariable linear regression analysis, rivaroxaban was independently associated with larger baseline hematoma volume (standardized linear regression coefficient: 0.581 [95% CI 0.146-1.015]; P = 0.009). Hematoma expansion (40.0% vs. 23.7%; P = 0.131) and hospital mortality (40.0% vs. 29.8%; P = 0.240) were similar between rivaroxaban and apixaban.
Conclusions:
Compared with apixaban, rivaroxaban pretreatment was independently associated with larger baseline hematoma volume in patients with spontaneous ICH. These findings require validation in larger cohort studies.
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Increased Intracranial Pressure l: Introduction
Venous Thrombosis III: Interprofessional Care
Increased Intracranial Pressure ll: Pathophysiology